Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.
Cancer Letters（2016）
Abstract
•The Ion PGM and AmpliSeq cancer panel can detect plasma ctDNA mutations from NSCLC.•ctDNA mutations in plasma are highly concordant to primary tumor tissue of NSCLC.•Our panel could be implemented for clinical use in a variety of advanced cancers.
MoreTranslated text
Key words
NSCLC,Circulating tumor DNA,Next generation sequencing,Ion PGM/AmpliSeq cancer panel,Targeted sequencing
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined